Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53
Main Authors: | Ou, Wen-Bin, Lu, Minmin, Eilers, Grant, Li, Hailong, Ding, Jiongyan, Meng, Xuli, Wu, Yuehong, He, Quan, Sheng, Qing, Zhou, Hai-Meng, Fletcher, Jonathan A |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104897/ |
Similar Items
-
HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status
by: Ou, Wen-Bin, et al.
Published: (2015) -
Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
by: Yang, Peipei, et al.
Published: (2016) -
High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines.
by: Ungar, S., et al.
Published: (1996) -
Regulation of p53: a collaboration between Mdm2 and MdmX
by: Pei, Dongsheng, et al.
Published: (2012) -
MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
by: Hirose, Mitsuaki, et al.
Published: (2014)